logo-loader

Tetra Bio-Pharma makes progress with inhaled THC-based drug in meeting with the FDA

Published: 16:27 16 Dec 2020 EST

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) CEO Guy Chamberland tells Proactive the group it held a Type B meeting with the FDA for an inhaled THC-based innovative drug for the treatment of chemotherapy-induced nausea and vomiting (CINV).

Chamberland says new drug will be part its global commercialization strategy to maintain a lead position in the treatment of CINV in patients with cancer, who failed to respond adequately to conventional anti-vomiting treatments. The inhaled THC drug, along with the Dronabinol Adversa drug product, will target global markets.

Tetra Bio-Pharma updates on progress made with inhaled cannabinoid-based...

Tetra Bio-Pharma (TSX:TBP, OTCQB:TBPMF) Inc. Guy Chamberland talks to Proactive about the significance of the response letter for a Type C meeting with the FDA for its inhaled cannabinoid-based product, QIXLEEF. Chamberland says the FDA has given the group clear guidance, which will allow Tetra...

on 30/3/22